echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > An imperfect healing light?

    An imperfect healing light?

    • Last Update: 2021-04-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The ADAURA study, which was unblinded in advance at the ASCO annual meeting in April 2020, became one of the most influential studies that year.


    However, the emergence of a new treatment model is bound to be accompanied by controversy and troubles, especially after the ADJUVANT study obtained a negative OS result, academic controversy intensified.


    Question 1: The primary end point of adjuvant therapy is DFS or OS?

    Question 1: The primary end point of adjuvant therapy is DFS or OS? Question 1: The primary end point of adjuvant therapy is DFS or OS?

    There is no doubt that overall survival (OS) is the gold standard reflecting the survival benefit of patients because it is well-defined, objective and robust, easy to measure, easy to interpret, and unbiased in measurement.


    The use of surrogate endpoints that reasonably predict clinical benefit in the early stages of clinical trials will speed up treatment evaluation and may reduce the cost of drug development.


    For advanced lung cancer, the goal of treatment is to improve survival and/or quality of life by reducing cancer-related symptoms; for early stage lung cancer, the goal of treatment is to improve long-term survival, so OS is used as a criterion for adjuvant therapy It seems the most appropriate.


    1.


    1.


    Friends who are interested in this issue recommend reading this article: Analysis of OS benefit in the presence of cross over

    2.


    2.


    For regulatory agencies, OS is more recognized as the primary endpoint of postoperative adjuvant treatment; however, DFS is currently recognized by more and more clinicians as an early alternative endpoint of OS.


    First, if DFS is long enough to enable more lung cancer patients to survive for more than 5 years and be cured, will we still be entangled with OS results?

    Second, it takes 8 to 10 years to obtain mature OS results.


    Nevertheless, it needs to be pointed out that DFS usually refers to the time from the start of randomization to the occurrence of tumor recurrence or death from any cause.


    3.


    3.


    ADJUVANT research design

    ADJUVANT research design ADJUVANT research design

    ADAURA research design

    ADAURA Research DesignADAURA Research Design

    The author has the following guesses about the reasons for the different results in the end:

    The author has the following guesses about the reasons for the different results in the end:

    First, prolonging the medication time may be related to a better prognosis.


    Second, a negative result of one study does not mean that other studies will also have negative results.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.